Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
NANO-X IMAGING LTD reports that SK square Co., Ltd. and SK Square Americas, Inc. have ceased to be beneficial owners of more than five percent of its Ordinary Shares. The filing is Amendment No. 1 to a previously filed Schedule 13G and states the Reporting Persons' ownership is 0.0% as shown on the cover information. The amendment is signed on 05/14/2026 and references a cover date of 03/31/2026.
Nano-X Imaging Ltd, an Israel-based medical imaging company, filed its annual report detailing an early-stage business with significant ongoing losses and substantial doubt about its ability to continue as a going concern. The company focuses on its Nanox.ARC and Nanox.ARC X multi-source digital X-ray systems, the Nanox.CLOUD platform, AI imaging solutions, and teleradiology services.
For the year ended December 31, 2025, Nano-X reported a net loss of approximately $75.0 million, working capital of about $50.0 million, shareholders’ equity of about $139.7 million, and an accumulated deficit of roughly $448.8 million. Operating cash flow was negative $40.8 million. Management and the independent auditor both highlight substantial doubt about the company’s ability to continue as a going concern without additional funding.
The report explains that Nano-X’s models—Subscription, CapEx, and prospective Licensing/OEM—remain unproven and depend heavily on third-party manufacturers, distributors, cloud vendors, and licensees. The company notes it has executed U.S. distribution agreements for about 360 CapEx systems over two to three years and is restructuring manufacturing, including closing a chip line in South Korea and shifting production to partners such as Fabrinet, Varex, and CEI. Nano-X also discloses it has an at-the-market Sales Agreement for up to $100 million in ordinary shares and had raised $46.1 million under this facility by December 31, 2025, but expects to need more capital to fund commercialization and deployment.
Nano-X Imaging Ltd. director Dan S. Suesskind has filed a Form 3, disclosing his initial equity holdings in the company. The filing lists ordinary shares underlying restricted share units (RSUs) and several stock option grants, but does not report any new buy or sell transactions.
The director reports 17,544 ordinary shares underlying RSUs granted on December 10, 2024, vesting in twelve equal quarterly installments through December 10, 2027. He also reports 7,792 ordinary shares underlying RSUs granted on December 10, 2025, vesting quarterly through December 10, 2028.
In addition, Suesskind holds stock options over 10,000 ordinary shares at an exercise price of $11.52 per share that are fully vested, plus options over 50,000 shares at $17.63 per share and 12,505 shares at $64.61 per share, which vest in equal quarterly installments until they become fully exercisable on future four-year anniversaries of their respective board approval dates.
Nano-X Imaging reported fourth-quarter 2025 revenue of $3.7 million, up from $3.0 million a year earlier, mainly from teleradiology and AI/software services. The company posted a GAAP net loss of $33.4 million versus $14.1 million, driven largely by a $17.5 million non-cash impairment tied to restructuring its Korean chip manufacturing line.
For full-year 2025, revenue reached $13.0 million with a net loss of $75.0 million. Nano-X is shifting to a more outsourced manufacturing model and expects about $18.0 million in total restructuring charges. Commercially, it has about 36 Nanox.ARC systems in deployment stages, expects roughly 17 additional systems to be installed in the coming months, and has U.S. distribution agreements for about 360 Capex systems over the next two to three years, though many systems are not yet generating revenue.
The company is targeting $35 million in 2026 revenue, but notes growth will depend on system activations and partner performance. Liquidity remains a key focus: as of December 31, 2025, cash, deposits and marketable securities totaled $60.0 million, after $40.8 million negative operating cash flow and $21.4 million positive financing cash flow in 2025. Nano-X also announced a planned CFO transition from Ran Daniel to Guy Nathanzon in mid-2026.
Nano-X Imaging reported fourth-quarter 2025 revenue of $3.7 million, up from $3.0 million a year earlier, mainly from teleradiology and AI/software services. The company posted a GAAP net loss of $33.4 million versus $14.1 million, driven largely by a $17.5 million non-cash impairment tied to restructuring its Korean chip manufacturing line.
For full-year 2025, revenue reached $13.0 million with a net loss of $75.0 million. Nano-X is shifting to a more outsourced manufacturing model and expects about $18.0 million in total restructuring charges. Commercially, it has about 36 Nanox.ARC systems in deployment stages, expects roughly 17 additional systems to be installed in the coming months, and has U.S. distribution agreements for about 360 Capex systems over the next two to three years, though many systems are not yet generating revenue.
The company is targeting $35 million in 2026 revenue, but notes growth will depend on system activations and partner performance. Liquidity remains a key focus: as of December 31, 2025, cash, deposits and marketable securities totaled $60.0 million, after $40.8 million negative operating cash flow and $21.4 million positive financing cash flow in 2025. Nano-X also announced a planned CFO transition from Ran Daniel to Guy Nathanzon in mid-2026.
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer. The filing lists direct holdings of ordinary shares and stock options, including options over 6,500, 12,500 and 40,000 ordinary shares with exercise prices between $11.52 and $23.86 and expirations from 2031 to 2033. A footnote explains that certain ordinary shares represent restricted share units granted on February 5, 2026, vesting in two equal installments over 12 and 24 months.
Nano-X Imaging Ltd. executive Saban Sharon, General Manager of the AI Division, reported his initial beneficial ownership in the company. He holds 26,316 ordinary shares directly, including shares underlying restricted share units granted on February 5, 2026 that vest 50% after 12 months and 50% after 24 months from the grant date. He also holds a stock option covering 15,000 ordinary shares at an exercise price of $17.63 per share, granted on September 15, 2022. These options vest in 16 equal quarterly installments of 6.25% each and are scheduled to be fully exercisable by September 15, 2026, with an expiration date of September 15, 2032.
Nano-X Imaging Ltd. director Erez Alroy filed an initial ownership report showing direct holdings of the company’s ordinary shares and stock options. He reports 6,962 ordinary shares in one line and 17,544 ordinary shares in another, reflecting different grant types.
Alroy also holds stock options covering 50,000 ordinary shares with a fixed exercise price of $17.63 per share that expire on December 28, 2032, and options over 10,000 ordinary shares at $11.52 per share expiring on December 31, 2033. Footnotes explain that one ordinary-share position consists of restricted share units granted on December 10, 2025, vesting in twelve equal monthly installments over one year, and that the option grants vest in 16 equal quarterly installments over four years from their respective reference dates.
Nano-X Imaging Ltd files Amendment No. 1 to its Form F-3 registration statement to furnish the form of indenture as Exhibit 4.7 and an updated consent of its independent auditors. The prospectus in Part I is unchanged. The registration contemplates sales "from time to time after the effective date".
The filing also restates corporate governance provisions under Israeli law: the company’s articles permit exculpation, indemnification and officers’ insurance to the fullest extent allowed, and indemnification caps include $50 million, 25% of shareholders’ equity, or aggregate offering proceeds, as described. The amendment is signed by the CEO and authorized U.S. agent on March 26, 2026.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of ordinary shares back to the company. On March 18, 2026, he transferred 39,474 ordinary shares to the issuer at a stated price of $0.00 per share. After this issuer-related disposition, he directly holds 46,424 ordinary shares, according to the filing.
Nano-X Imaging Ltd. director Ronen Nehama filed an initial ownership report showing his equity position in the company. The filing lists a stock option to buy 50,000 ordinary shares at an exercise price of $17.63 per share, expiring on December 31, 2033, alongside direct holdings of ordinary shares, including shares underlying restricted share units that vest in twelve equal monthly installments from a December 10, 2025 grant.